<DOC>
	<DOC>NCT00160524</DOC>
	<brief_summary>An open-label follow-on safety study of CDP870 (400 mg every 4 weeks) in patients with Crohn's Disease who have completed a 26-week blinded study (CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]).</brief_summary>
	<brief_title>A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>Participation in either of the CDP870031 [NCT00152490] or CDP870032 [NCT00152425] clinical studies in which the subject completed the trial at Week 26. Subjects may have received active or placebo or both treatments in the prior study Subjects must be able to understand the information provided to them and give written informed consent Any exclusion criterion that would have prevented the subject's participation in the qualifying pivotal study CDP870031 [NCT00152490] or CDP870032 [NCT00152425], although the criterion that excludes previous participation in a clinical trial of Certolizumab Pegol does not apply. In addition there are no limits on the Clinical Disease Activity Index (CDAI) score at entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Certolizumab Pegol</keyword>
	<keyword>Cimzia</keyword>
	<keyword>CDP870</keyword>
	<keyword>CZP</keyword>
</DOC>